Loading
A phase 2 trial of Envafolimab in advanced solid tumours, run by 3D Medicines (Sichuan) Co., Ltd., now recruiting.
KN035 for dMMR/MSI-H Advanced Solid Tumors is a phase 2 interventional study registered as NCT03667170 by 3D Medicines (Sichuan) Co., Ltd., with 200 participants planned, started 2018-08-22 and due to reach its primary completion in 2026-12-30. Interventions recorded: KN035.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares 3D Medicines, Envafolimab, Monoclonal antibodies, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares 3D Medicines, Envafolimab, Monoclonal antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares 3D Medicines, Envafolimab, Monoclonal antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares Monoclonal antibodies, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Monoclonal antibodies, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/